BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Leitner GC, Vogelsang H. Pharmacological- and non-pharmacological therapeutic approaches in inflammatory bowel disease in adults. World J Gastrointest Pharmacol Ther 2016; 7(1): 5-20 [PMID: 26855808 DOI: 10.4292/wjgpt.v7.i1.5] [Cited by in CrossRef: 32] [Cited by in F6Publishing: 35] [Article Influence: 5.3] [Reference Citation Analysis]
Number Citing Articles
1 Yoo HK, Byun HG, Caprioli F, Fumery M, Peyrin-biroulet L, Sreedhar S, Potter J, Jang M. Budget impact analysis of the subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in the Big-5 European (E5) countries. BMC Health Serv Res 2022;22:1319. [DOI: 10.1186/s12913-022-08683-y] [Reference Citation Analysis]
2 Mousavi T, Hassani S, Baeeri M, Rahimifard M, Vakhshiteh F, Gholami M, Ghafour-broujerdi E, Abdollahi M. Comparison of the safety and efficacy of fingolimod and tofacitinib in the zebrafish model of colitis. Food and Chemical Toxicology 2022. [DOI: 10.1016/j.fct.2022.113509] [Reference Citation Analysis]
3 Yasmin F, Najeeb H, Naeem U, Moeed A, Koritala T, Surani S. Apheresis: A cell-based therapeutic tool for the inflammatory bowel disease. World J Clin Cases 2022; 10(21): 7195-7208 [DOI: 10.12998/wjcc.v10.i21.7195] [Reference Citation Analysis]
4 Mishra J, Stubbs M, Kuang L, Vara N, Kumar P, Kumar N, Subramanian VS. Inflammatory Bowel Disease Therapeutics: A Focus on Probiotic Engineering. Mediators of Inflammation 2022;2022:1-15. [DOI: 10.1155/2022/9621668] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
5 Ren J, Yan D, Wang Y, Zhang J, Li M, Xiong W, Jing X, Li P, Zhao W, Xiong X, Wu M, Zhong G. Inhibitor of Differentiation-2 Protein Ameliorates DSS-Induced Ulcerative Colitis by Inhibiting NF-κB Activation in Neutrophils. Front Immunol 2021;12:760999. [PMID: 34804049 DOI: 10.3389/fimmu.2021.760999] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Xu Y, Baylink DJ, Cao H, Xiao J, Abdalla MI, Wasnik S, Tang X. Inflammation- and Gut-Homing Macrophages, Engineered to De Novo Overexpress Active Vitamin D, Promoted the Regenerative Function of Intestinal Stem Cells. Int J Mol Sci 2021;22:9516. [PMID: 34502422 DOI: 10.3390/ijms22179516] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
7 Adriana Estrella GR, María Eva GT, Alberto HL, María Guadalupe VD, Azucena CV, Sandra OS, Noé AV, Francisco Javier LM. Limonene from Agastache mexicana essential oil produces antinociceptive effects, gastrointestinal protection and improves experimental ulcerative colitis. J Ethnopharmacol 2021;280:114462. [PMID: 34324951 DOI: 10.1016/j.jep.2021.114462] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
8 Mousavi T, Nikfar S, Abdollahi M. Comprehensive study on the administrative, economic, regional, and regulatory prospects of complementary and alternative medicine (CAM) in inflammatory bowel disease (IBD). Expert Rev Clin Pharmacol 2021;14:865-88. [PMID: 33993811 DOI: 10.1080/17512433.2021.1925108] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Ferreira-Duarte M, Rodrigues-Pinto T, Sousa T, Faria MA, Rocha MS, Menezes-Pinto D, Esteves-Monteiro M, Magro F, Dias-Pereira P, Duarte-Araújo M, Morato M. Interaction between the Renin-Angiotensin System and Enteric Neurotransmission Contributes to Colonic Dysmotility in the TNBS-Induced Model of Colitis. Int J Mol Sci 2021;22:4836. [PMID: 34063607 DOI: 10.3390/ijms22094836] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
10 Kalyon S, Gökden Y, Oyman F. A new biological marker in inflammatory bowel disease: Pentraxin 3. Journal of Surgery and Medicine 2020;4:875-878. [DOI: 10.28982/josam.791156] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
11 Chulkina MM, Pichugin AV, Ataullakhanov RI. Pharmaceutical grade synthetic peptide Thr-Glu-Lys-Lys-Arg-Arg-Glu-Thr-Val-Glu-Arg-Glu-Lys-Glu ameliorates DSS-induced murine colitis by reducing the number and pro-inflammatory activity of colon tissue-infiltrating Ly6G+ granulocytes and Ly6C+ monocytes. Peptides 2020;132:170364. [PMID: 32621844 DOI: 10.1016/j.peptides.2020.170364] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
12 Bhatti S, Jaafar I, Hassan H, Atassi H, Stocker A, Hughes M, Pinkston C, Dryden G, Abell T. Effects of Gastric Neuromodulation on Crohn's Disease in Patients With Coexisting Symptoms of Gastroparesis. Neuromodulation: Technology at the Neural Interface 2020;23:1196-200. [DOI: 10.1111/ner.13118] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
13 Lázaro CM, de Oliveira CC, Gambero A, Rocha T, Cereda CMS, de Araújo DR, Tofoli GR. Evaluation of Budesonide-Hydroxypropyl-β-Cyclodextrin Inclusion Complex in Thermoreversible Gels for Ulcerative Colitis. Dig Dis Sci 2020;65:3297-304. [PMID: 31974913 DOI: 10.1007/s10620-020-06075-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
14 Worel N, Mansouri Taleghani B, Strasser E. Recommendations for Therapeutic Apheresis by the Section "Preparative and Therapeutic Hemapheresis" of the German Society for Transfusion Medicine and Immunohematology. Transfus Med Hemother 2019;46:394-406. [PMID: 31933569 DOI: 10.1159/000503937] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
15 Balendran K, Udumalagala S, Nawaraththne NMM. Pyloric stenosis as a manifestation of isolated gastric Crohn's disease responding to intralesional steroid injection and balloon dilation: a case report. J Med Case Rep 2019;13:331. [PMID: 31718712 DOI: 10.1186/s13256-019-2272-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
16 Ait-oudhia S, Lien YTK, Basu S, Lesko L, Schmidt S. Application of Pharmacometrics and Systems Pharmacology to Current and Emerging Biologics in Inflammatory Bowel Diseases. Quantitative Pharmacology and Individualized Therapy Strategies in Development of Therapeutic Proteins for Immune-Mediated Inflammatory Diseases 2019. [DOI: 10.1002/9781119289234.ch10] [Reference Citation Analysis]
17 Han CJ, Heitkemper MM. Gastrointestinal Disorders. Handbook of Sleep Disorders in Medical Conditions 2019. [DOI: 10.1016/b978-0-12-813014-8.00017-2] [Reference Citation Analysis]
18 Kamp KJ, Brittain K. Factors that Influence Treatment and Non-treatment Decision Making Among Individuals with Inflammatory Bowel Disease: An Integrative Review. Patient 2018;11:271-84. [PMID: 29313266 DOI: 10.1007/s40271-017-0294-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
19 Mosli M, Alfaer S, Almalaki T, Albeshry A, Aljehani S, Alshmrani B, Habib Z, Jawa H, Qari Y. Baseline risk assessment of patients with ulcerative colitis: does initial treatment selection influence outcomes? Eur J Gastroenterol Hepatol 2019;31:80-5. [PMID: 30199472 DOI: 10.1097/MEG.0000000000001249] [Reference Citation Analysis]
20 Ferri D, Gaviña P, Parra M, Costero AM, El Haskouri J, Amorós P, Merino V, Teruel AH, Sancenón F, Martínez-Máñez R. Mesoporous silica microparticles gated with a bulky azo derivative for the controlled release of dyes/drugs in colon. R Soc Open Sci 2018;5:180873. [PMID: 30225077 DOI: 10.1098/rsos.180873] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
21 Khazraei H, Bananzadeh A, Hosseini SV. Early Outcome of Patient with Ulcerative Colitis who Received High Dose of Steroid and Underwent Two Staged Total Proctocolectomy. Adv Biomed Res 2018;7:11. [PMID: 29456982 DOI: 10.4103/abr.abr_175_16] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
22 Maruszewska-Cheruiyot M, Donskow-Łysoniewska K, Doligalska M. Helminth Therapy: Advances in the use of Parasitic Worms Against Inflammatory Bowel Diseases and its Challenges. Helminthologia 2018;55:1-11. [PMID: 31662622 DOI: 10.1515/helm-2017-0048] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 4.5] [Reference Citation Analysis]
23 Ono K, Nimura S, Hideshima Y, Nabeshima K, Nakashima M. Orally administered sodium 4-phenylbutyrate suppresses the development of dextran sulfate sodium-induced colitis in mice. Exp Ther Med 2017;14:5485-90. [PMID: 29285080 DOI: 10.3892/etm.2017.5251] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
24 Dubois-Camacho K, Ottum PA, Franco-Muñoz D, De la Fuente M, Torres-Riquelme A, Díaz-Jiménez D, Olivares-Morales M, Astudillo G, Quera R, Hermoso MA. Glucocorticosteroid therapy in inflammatory bowel diseases: From clinical practice to molecular biology. World J Gastroenterol 2017; 23(36): 6628-6638 [PMID: 29085208 DOI: 10.3748/wjg.v23.i36.6628] [Cited by in CrossRef: 73] [Cited by in F6Publishing: 71] [Article Influence: 14.6] [Reference Citation Analysis]
25 Habibi F, Habibi ME, Gharavinia A, Mahdavi SB, Akbarpour MJ, Baghaei A, Emami MH. Quality of life in inflammatory bowel disease patients: A cross-sectional study. J Res Med Sci 2017;22:104. [PMID: 29026420 DOI: 10.4103/jrms.JRMS_975_16] [Cited by in Crossref: 27] [Cited by in F6Publishing: 32] [Article Influence: 5.4] [Reference Citation Analysis]
26 Cabriada J, Rodríguez-lago I. Granulocitoaféresis en 2017. Puesta al día. Enfermedad Inflamatoria Intestinal al Día 2017;16:62-69. [DOI: 10.1016/j.eii.2016.12.001] [Reference Citation Analysis]
27 Gerçeker E, Yüceyar H, Kasap E, Demirci U, Ekti BC, Aydoğdu İ, Miskioğlu M. Treatment of inflammatory bowel disease by leukocytapheresis. Transfus Apher Sci 2017;56:421-6. [PMID: 28454883 DOI: 10.1016/j.transci.2017.03.016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
28 Inayat F, Ullah W, Hussain Q, Shafique K. Crohn's disease presenting as gastric outlet obstruction: a therapeutic challenge? BMJ Case Rep 2017;2017:bcr-2016-218181. [PMID: 28455456 DOI: 10.1136/bcr-2016-218181] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
29 Yun JW, Minagar A, Alexander JS. Emerging Roles of Endothelial Cells in Multiple Sclerosis Pathophysiology and Therapy. Inflammatory Disorders of the Nervous System 2017. [DOI: 10.1007/978-3-319-51220-4_1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
30 Goetsch AL, Kimelman D, Woodruff TK. Digestive Autoimmune Diseases: Inflammatory Bowel Disease. Fertility Preservation and Restoration for Patients with Complex Medical Conditions 2017. [DOI: 10.1007/978-3-319-52316-3_15] [Reference Citation Analysis]
31 Kamysz E, Sałaga M, Sobocińska M, Giełdoń A, Fichna J. Anti-inflammatory effect of novel analogs of natural enkephalinase inhibitors in a mouse model of experimental colitis. Future Medicinal Chemistry 2016;8:2231-43. [DOI: 10.4155/fmc-2016-0156] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
32 Muthas D, Reznichenko A, Balendran CA, Böttcher G, Clausen IG, Kärrman Mårdh C, Ottosson T, Uddin M, MacDonald TT, Danese S, Berner Hansen M. Neutrophils in ulcerative colitis: a review of selected biomarkers and their potential therapeutic implications. Scand J Gastroenterol 2017;52:125-35. [PMID: 27610713 DOI: 10.1080/00365521.2016.1235224] [Cited by in Crossref: 95] [Cited by in F6Publishing: 81] [Article Influence: 15.8] [Reference Citation Analysis]
33 Passot C, Mulleman D, Bejan-Angoulvant T, Aubourg A, Willot S, Lecomte T, Picon L, Goupille P, Paintaud G, Ternant D. The underlying inflammatory chronic disease influences infliximab pharmacokinetics. MAbs 2016;8:1407-16. [PMID: 27589009 DOI: 10.1080/19420862.2016.1216741] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 7.2] [Reference Citation Analysis]
34 Sen A, Yuksel M, Bulut G, Bitis L, Ercan F, Ozyilmaz-yay N, Akbulut O, Cobanoğlu H, Ozkan S, Sener G. Therapeutic Potential of Myrtus communis Subsp. communis Extract Against Acetic ACID-Induced Colonic Inflammation in Rats: THERAPEUTIC POTENTIAL OF MYRTUS COMMUNIS SUBSP. COMMUNIS EXTRACT. Journal of Food Biochemistry 2017;41:e12297. [DOI: 10.1111/jfbc.12297] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]